ligands, but demonstrated only a limited characterization and utility of these as time-resolved fluorescent labels (9, 10). Here we provide a detailed characterization and demonstration of utility for improved Ru(ll) chelates based on ECL. Labels based on such Ru(ll) complexes offer several distinct advantages over existing labels, namely, resistance to heat and chemical challenges, ease of labeling, and lack of interferences from endogenous metal ions, as demonstrated in the following study.
made use of this rapid sample preparation offered by PCR to develop similarly rapid and simple assays based on electrochemiluminescence (ECL) (6, 7) . In developing nucleic acid hybridization formats, we have focused on labeling reagents based on electro-generated chemiluininescence (8). The label described here is a phosphoramidite of the tris(2,2'-bipyridine)ruthenium(II) complex, bis(2,2-bipyridine){4-[4-(2-cyanoethoxy-N,N-diisopropylamino)phosphinoxybutyl]4'-methyl}2,2-bipyridine ruthenium(II) dihexafluorophosphate (Ongen#{174} Phosphoramidite; IGEN Inc., Rockville, MD). We have earlier described initial results with these complexes as an N-hydroxysuccinamide ester (NHS) (6, 7). Others have also described related
Ru(II) complexes with bathophenanthroline
ligands, but demonstrated only a limited characterization and utility of these as time-resolved fluorescent labels (9, 10). Here we provide a detailed characterization and demonstration of utility for improved Ru(ll) chelates based on ECL. Labels based on such Ru(ll) complexes offer several distinct advantages over existing labels, namely, resistance to heat and chemical challenges, ease of labeling, and lack of interferences from endogenous metal ions, as demonstrated in the following study.
We have made use of the phosphoramidite chemistry utilized on many automated DNA synthesizers to generate a phosphoramidite of this Ru(ll) complex, Origen phosphoramidite, to improve the application and utility of these ECL labels in the clinical laboratory. Given its inherent stability, this new labeling reagent can be used to readily generate probes with an automated synthesizer. Also, the probes so labeled are unaffected in their ability to hybridize, unlike enzyme-labeled probes (11) . To demonstrate the clinical value of this labeling reagent, we have used it to develop assays for the detection and quantification of the HIV1 gag gene and have applied these assays to clinical samples.
Materials and Methods Synthesisof Ongen Phosphoramidite
The C-4 bipynidine ligand was synthesized by alkylation of 4,4'-dimethyl-2,2'-bipyridine with 2-(2-bromoethyl)-1,3-dioxalane (12). The alkylated product, 4-[3-(1 ,3-dioxalan-2-yl)propyl]-4'-methyl-2,2 '-bipyridine, was converted to the corresponding aldehyde by acid hydrolysis. The sodium borohydride reduction of the aldehyde resulted in production of 4-(4-hydroxybutyl)-4'-methyl-2,2 '-bipyridine (bipyridine ligand). After this ligand synthesis, we refluxed 800 mg (-3.3 mmol) of the bipynidine ligand with 1.56 g (3.0 mmol) of cis-dichloro-bis(2,2'-bipyridine)ruthenium(H) dihydrate in 100 mL/L ethanol reagent for 6 h to obtain the 
SK39
Ru(II) :ATCCTGGGATTAAATAAAATAGTAA-GAATGTATAGCCCTAC SK19
Labeling Oligonucleotides
All the synthetic oligonucleotides were purified to remove any contaminating amino groups by gel filtration on a Biogel P6 (Bio-Rad Labs., Richmond, CA) column. Biotin was introduced via the 5'-amino group of oligonucleotides lambda 1C, 2PV6, and SK39 using an NHS eater of biotin (Clontech) (15) . Typically the oligonucleotides, (0.1 anol in 100 1zL of PBS, pH 7.4) were reacted with 3.3 mg of NHS-biotin dissolved in 100 iL of dimethyl sulfoxide overnight at room temperature in the dark. Oligonucleotides were recovered from these labeling reactions by ethanol precipitation. For lambda 1C this biotinylated product was purified by HPLC to form our standard.
In the other cases purification was not needed because the labeling efficiencies were >90% and produced excellent results.
Oligonucleotide lambda was labeled with P by using T4 polynucleotide kinase and established methods to generate a probe with a specific activity of -3000 kCi/mol (16). This 32P-labeled probe was diluted with unlabeled oligonucleotide lambda to allow the probes to be used at higher concentrations during hybridization, which enabled the P probe to hybridize with the same kinetics as our Onigen phosphoramidite-labeled oligonucleotide. After this dilution, the probe had a specific activity of 33 kCi/mol, and 0.2 pCi of probe was used per assay.
PolymeraseChain Reaction
PCR was performed essentially as described (5, 17) Melting studies monitored by the hypochromic shift at 260 nm were carried out in the temperature-controlled cell of a Hitachi (Tokyo, Japan) U3200 dualwavelength spectrophotometer. We analyzed the denaturation of two hybrids-one of lambda (unlabeled) and lambda 1C, and one of lambda 1 (Origen phosphoramidite label) and lambda iC-as follows. One sample of lambda was hybridized to lambda 1C (1. 64 mmol/L) in Tris-saline (500 mmol/L NaCl, 10 mmol/L Tris -HC1, pH 7.4). The other sample was labeled lambda 1 hybridized to lambda 1C (1.05 mmol/L), also in Tris-saline. These samples were introduced at different times into matched cuvettes blanked against buffer and heated at 1 #{176}C/min; Tris-saline was the control sample. This assay was repeated three times. The data were averaged, normalized, and corrected for the phosphoramidite label absorbance at 260 nm. Melting studies of oligonucleotides on beads were carried out with preformed hybrids of either lambda (32P-labeled) or lambda 1 (phosphoramidite-labeled), 114 pmol, and lambda 1C (biotinylated), 60 pmol, hybridized at 50#{176}C for 20 mm. These complexes were captured on 1.5 mg of our streptavidin beads and washed (6). Beads with the bound hybrids, 50 pg (500 pL) per assay, were incubated at various tem- 1C (biotinylated) on beads (0.1 pmol on 80 pg of beads per assay) and hybridizing lambda 1 (phosphoramidite-labeled) or lambda (32P-labeled), depending on the assay, with addition of 0.3 pmol of lambda 1 or lambda per assay in 500 pL of Onigen assay buffer. Samples were hybridized for various times, after which the hybrids were separated from the unhybridized probe by using a magnetic rack and removing the supernatant. These beads were resuspended in 600 pL of Origen assay buffer and analyzed with the Origen I analyzer or the LS-100C liquid scintillation counter, depending on the sample. Readings were taken in triplicate, the background data were subtracted, and the results were normalized to the signal from the lambda (32P-labeled) samples hybridized for 3 h. Data were plotted relative to the 3-h point.
To buffer, after which ECL was quantified in the Origen I Figure 2a . To confirm these data on the denaturation temperature profile more rigorously, we analyzed denaturation of preformed hybrids from the surface of beads by using our ECL assay and assay. These results (Figure 2b) showed that the denaturing temperature profiles for these sequences were virtually identical.
Studies into the kinetics of hybridization were initially hampered by our present assay format, the rate of hybridization being too rapid (<1 mm) to allow accurate determination.
We therefore diluted the concentration to allow a slower rate for hybridization to our beadbound target. The results (Figure 3) To determine the relative merits of our label and a system for labeling, we developed a set of standards and a set of samples from dilutions of a synthetic biotiny- To determine the effectiveness of these phosphoramidite-labeled probes in assays, we used previously developed assays based on an NHS ester-labeling protocol (6, 7). One of these formats made use of the ability to directly modulate the signal on bead binding, which yields a rapid nonseparation assay (6); the other made use of a denaturing wash step followed by hybridization to saturation to give an assay with more accurate results (7). The results for the rapid nonseparation assay (Table 1 ) demonstrate the assay's ability to detect 500 and 5000 copies of the HP/-i gag gene and to discriminate these from negative samples. The assay for more precise determination of a specific DNA, as described in Materials and Methods and previously demonstrated for the NHS ester labeling (7) , was used to study a selection of clinical DNA isolates. Analysis of clinical samples was carried out with reference to standard curves run with each assay, as described above. In the AIDS patients' samples, 80% were positive; the normal control samples were 90% negative. In contrast, the group of AIDS patients with PML gave only 60% positives. The samples were scored as positive when 30 copies of HP/-i were detected, based on the linear-regression analysis of the standard curves described above. Samples with <30 copies were considered as zero because these values were usually outside the statistically significant range of the data from the standard curve. label has the required properties to be a valuable nucleic acid probe without the need to establish new hybridization conditions for use. This has not been the case with previously described probes, where the modifications have led to lower hybridization temperatures because of interference of the labels (enzymes and biotin) with the stability of the hybridization or of the resulting signal (11,23).
Discussion

Stability of the
Our studies of the kinetics of hybridization also showed that the addition of the phosphoramidite label had little effect on the probes' kinetics, with the rates for Ru(ll)-labeled probes and 32P-labeled probes being identical. This information, combined with the denaturation results, indicates that in most cases the performance of these synthetically labeled oligonucleotides will be identical to that of the native sequences. This equivalence of labeled probes allows us to draw on the existing information regarding specificity and selectivity of DNA probe sequences, leading us to expect that similar re. suits will be obtained with the ECL system. One explanation is that these samples were contaminated during DNA isolation because no patient information suggests any HIV-1 exposure or infection. The low amounts of HP/-i in the peripheral blood leukocyte DNA of these AIDS patients indicates that increasing the sensitivity of the assay would be valuable.
In conclusion, the results of the HP/-i gag gene studies clearly demonstrate the utility of this new label for the production of labeled oligonucleotides with the desired properties for use as a probe. The application of the Origen phosphoramidite to the automated synthesis of probes for other assays involving PCR is simple, allowing the development of rapid and practical assays. These properties will make these ECL levels and detection systems of great value to both research and clinical studies. These conclusions are supported by the model assay and demonstration of its application to the detection and quantification of the HP/-i gag gene in clinical samples. The development of improved instrumentation has allowed improved sensitivity and allows the inclusion of internal controls and use of multiple wavelengths with alternative labels. A more extensive study of HP/ in a longitudinal study of virus burden in peripheral blood lymphocytes during therapy would be of interest. Studies are also in progress for using these probes for direct detection of nucleic acid in clinical samples without the need for amplification.
